With the development of nanotechnology, multiple materials including lipid, polymers, and metals, have been widely applied to design drug delivery systems, especially for cancer therapy. To this end, micelles have drawn high attention in nano-drug delivery systems for targeted cancer therapy due to their attractive features. Despite plain micelles having been proved to alleviate the side-effects of their loading drugs, the therapy outcomes are usually unsatisfied partially due to ineffective drug release and endosome entrapment. With the experience research team and advanced instruments, Creative Biolabs launches a novel Mi-LOAD™ micelles technology platform that exploits universal cancer and immune therapeutic targets to diagnose and treat cancer. Our Mi-LOAD™ micelles technology platform is created to provide professional technology and outstanding service to help patients across the continuum of cancer care, including solid tumor therapeutics, agents for real-time image-guided surgery, and T cell activating immunotherapies.
The core technology of Mi-LOAD™ micelles is comprised of ultra pH-sensitive polymeric micelles that have been engineered to encapsulate and protect a wide variety of payloads, and selectively release them upon exposure to acidic biological environments within tumors and endosomes. The micelles can encapsulate imaging and therapeutic payloads for systemic administration to specifically target the acidic tumor microenvironment which is a hallmark of all solid tumors, as well as minimizing exposure to normal tissues. Micelles can be potentially applied generally to any solid tumor by using pH as a biomarker for cancer without its oncogenic phenotype.
Fig.1 Mechanism of micelles. (Liao, 2018)
Except for therapeutic delivery, proprietary micelle compositions are developed to activate stimulator of interferon genes (SIG), a ubiquitous immune signaling molecule for T cell therapy of solid tumors. Moreover, non-canonical SIG activation is achieved through polyvalency in an unprecedented and advantageous manner. The bind of the natural SIG ligand cGAMP with SIG-activating polymers further synergizes innate immune activation leading to highly efficacious T cell immunity against solid cancers.
This platform is mainly to deliver payloads to the target. The proprietary product candidate contains pegsitacianine intraoperative imaging agent and the key strategic partners of this drug delivery platform are two cooperation projects with big pharma.
This platform is mainly to activate the polyvalent SIG. The proprietary product candidate contains cGAMP and OMNI polymers which can yield robust trafficking of the immune system to treat solid cancers by dual activation of SIG.
If you are interested in more details about our Mi-LOAD™ micelles technology, please do not hesitate to contact us.
Reference
For Research Use Only | Not For Clinical Use
Download our brochure